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Letter to the EditorHereditary spherocytosis and the (TA)nTAA polymorphism of
UGT1A1 gene promoter region—A comparison of the bilirubin
plasmatic levels in the different clinical forms
To the editor,
Hereditary spherocytosis (HS) is the most common non-
immune hemolytic anemia in individuals of northern European
ancestry, affecting 1 in 2000 [1]. HS is classiﬁed as mild, moderate
or severe according to the severity of the symptoms, family history
and analytical presentation—hemoglobin (Hb) concentration, reti-
culocyte count and serum bilirubin levels [1]. When performing the
classiﬁcation of HS in our patients during the last years, we
observed that bilirubin levels were sometimes inconsistent with
the other parameters deﬁning the severity of this anemia. This was
particularly evident in some mild HS cases that presented
unexpectedly high bilirubin plasma concentration, which was not
in agreement with the other analytical parameters. A potential
cause for this discrepancy could be the co-inheritance of HS andFig. 1. Bilirubin plasmatic levels according to UGT1A1 polymorphism for (A) control gr
unsplenectomised HS patients according to their clinical classiﬁcation (mild, moderate or se
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Whitney U test); epb0.01 mild HS patients vs. moderate HS patients or severe HS patientsGilbert's syndrome (GS). This syndrome, which is estimated to
affect 3-10% of the general population [2,3], is a metabolic disorder
characterized by a mild and chronic unconjugated hyperbilirubi-
nemia, in the absence of liver and hematologic disease. A
polymorphism in the promoter of the bilirubin uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) gene, which expresses the
speciﬁc isoform for bilirubin conjugation in the liver, has been
shown to associate GS with a decrease of enzymatic activity to
about 30% [4,5]. The majority of the GS individuals are homozygous
for a TA duplication in the (TA)nAA motif of the promoter region of
UGT1A1 gene [c.-41_-40dupTA]; this is characteristic of the
Caucasian population [2–5], in general, as well as of the Portuguese
population [6], in particular. The co-inheritance of HS and GS can
exacerbate hyperbilirubinemia, and, therefore, it could be a
confounding factor to deﬁne HS severity. The aim of our work
was to evaluate the prevalence of GS in HS patients and how this
co-inheritance may confound the clinical classiﬁcation of HS and its
prognosis. We evaluated bilirubin plasmatic concentration and
UGT1A1 gene polymorphisms in 48 healthy individuals and in 125
patients diagnosed with HS by standard screening tests (43
splenectomised and 82 unsplenectomised). The patients wereoup and total unsplenectomised HS patients (unspl HS) and (B) control group and
vere HS). Data presented as median values (inter-quartile range). ⁎pb0.05 (TA)7/(TA)7
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Table 1
Bilirubin plasmatic levels for control group and unsplenectomised and splenectomised
HS patients according to clinical classiﬁcation (mild, moderate or severe HS).
Bilirubin (μmol/L)
Control (n=48) 8.0 (5.6–10.7)
HS patients Unsplenectomised Splenectomised
Total (n=82/n=43) 26.2⁎⁎⁎ (10.3–52.6) 13.7⁎⁎⁎§§ (10.3–21.0)
Mild HS (n=49/n=7) 15.7⁎⁎ (7.0–32.2) 11.3 (7.9–13.8)
Moderate HS (n=27/n=22) 42.8⁎⁎⁎££ (29.8–66.7) 14.6⁎⁎⁎§§§ (11.2–24.9)
Severe HS (n=6/n=14) 43.5⁎⁎⁎£ (28.6–94.0) 15.4⁎⁎§ (9.8–25.1)
Data presented as median values (inter-quartile range).
⁎⁎pb0.01, ⁎⁎⁎pb0.001 control group vs. HS patients (Mann–Whitney U test).
§pb0.05, §§pb0.01, §§§pb0.001 unsplenectomised vs. splenectomised HS patients
(Mann–Whitney U test).
£pb0.05, ££pb0.01 mild HS patients vs. moderate or severe HS patients (Mann–
Whitney U test).classiﬁed as having mild, moderate and severe HS, according to
Bolton-Maggs et al. [1]; for splenectomised patients, we used the
clinical classiﬁcation of HS established before splenectomy. We
evaluated plasmatic total bilirrubin levels and the TA duplication in
the repetitive TATA box sequence of the UGT1A1 gene promoter,
screened by acrylamide gel (15%) analysis of polymerase chain
reaction products [6]. The studied subjects were grouped according
to the gene polymorphism—(TA)6/(TA)6 for homozygote indivi-
duals with normal UGT1A1 transcription, (TA)6/(TA)7 for hetero-
zygote individuals and (TA)7/(TA)7 for individuals with GS.
For the UGT1A1 polymorphism, we found in control group
that 45.8%, 47.9% and 6.3% of the individuals were (TA)6/(TA)6,
(TA)6/(TA)7 and (TA)7/(TA)7, respectively; in the total HS
patients (unsplenectomised plus splenectomised), we found
similar frequencies—43.2%, 48.0% and 8.8%, respectively; actually,
no statistically signiﬁcant differences were found between
control and HS groups (p=0.846, Pearson χ2). The prevalence
of GS in both groups was within the estimated range [2,3]. In the
control group, unsplenectomised (Fig. 1A) and splenectomised
(data not shown) HS patients, bilirubin was higher in (TA)7/
(TA)7 individuals, followed by the (TA)6/(TA)7 and (TA)6/(TA)6
subjects. This is likely to result from a decrease in UGT1A1 gene
expression, which is reﬂected in altered enzyme activity, as
described elsewhere [7].
Studying the unsplenectomised patients according to HS
severity (Fig. 1B), we observed that in mild HS patients, the
(TA)7/(TA)7 individuals presented signiﬁcantly higher values of
bilirubin, as compared to the other genotypes. Moreover, the
bilirubin levels in these individuals were even higher than in
(TA)6/(TA)6 moderate and severe HS patients. In moderate HS, the
bilirubin levels of GS individuals were only increased when
compared to the (TA)6/(TA)6 subjects. As we had no severe HS
patients presenting the (TA)7/(TA)7 genotype, we could not
ascertain about their bilirubin levels.
Both splenectomised and unsplenectomised HS patients presented
a statistically signiﬁcant higher bilirubin levels when compared to the
control group (Table 1); unsplenectomised patients also presented
signiﬁcantly higher bilirubin values than splenectomised patients, as
splenectomy improves the hemolytic features and removes anemia. In
both HS groups, the bilirubin concentration increased with HS
severity reaching a signiﬁcant difference in unsplenectomised HS
patients.
We must emphasize that, in (TA)7/(TA)7 patients with mild HS,
66% of them presented a bilirrubin concentration higher than 34 μM,
the highest reference value deﬁned for mild HS cases [1]; in patients
with moderate HS, 50% of them also presented a bilirrubin concen-
tration higher than 51 μM, the highest value deﬁned for moderate HS
cases [1].In conclusion, our data show that the co-inheritance of GS can be
misleadingwhen deﬁning the severity of HS, and, therefore, it would be
important to study the UGT1A1 gene polymorphismwhen the bilirubin
values are not in accordance with the other parameters used to deﬁne
HS severity. Moreover, it is known that the co-inherence of GS with HS
increases the risk for the development of gallstones in HS children [8];
therefore, these studies could also be valuable in future clinical
decisions, namely to decide about the performance of splenectomy.
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